Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05543993 · ClinicalTrials.gov registry record
COVID Booster in Pregnancy and Lactation
A clinical trial, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- 150
- Enrollment target
NCT05543993: Completed study, sponsored by Thomas Jefferson University.
NCT05543993 is a clinical trial that has completed, run by Thomas Jefferson University. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05543993 has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
Primary Outcome
Quantitative Maternal IgG to SARS CoV2 spike and other domains
Interventions
- DRUG Bivalent COVID-19 Booster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-09-29 |
| Est. Completion | 2024-06-10 |
What the finished NCT05543993 record still lists
NCT05543993 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Bivalent COVID-19 Booster is the first listed.
NCT05543993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05543993 about?
NCT05543993 is a clinical study titled "COVID Booster in Pregnancy and Lactation". This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.
What is the current status of trial NCT05543993?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2022-09-29. Estimated completion is 2024-06-10.
What interventions are being tested in trial NCT05543993?
The interventions under investigation include: Bivalent COVID-19 Booster (DRUG).
Who is sponsoring clinical trial NCT05543993?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI